Multimodal Stratification Of Predictive Biomarkers In Head And Neck Cancers: A Focus On Cytokine-Based Immunotherapy

Cytokine-based immunotherapy is emerging as a promising treatment for head and neck cancers, yet patient response remains highly variable — some benefit significantly, while others face severe side effects. To improve outcomes and reduce risks, there's a growing need to predict which patients are most likely to respond.

This research explores the role of predictive biomarkers, specifically the expression of immune checkpoint molecules like PD-L1 and TIGIT, alongside cytokine profiling within the tumor microenvironment, to better understand individual immune responses. Unlock deeper insights into how these biomarkers can help personalize cytokine-based therapies and drive more effective, targeted treatment strategies by exploring the full findings.